Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Ana Estévez-Braun
Correction: CM363, a Novel Naphthoquinone Derivative Which Acts as Multikinase Modulator and Overcomes Imatinib Resistance in Chronic Myelogenous Leukemia
Oncotarget
Oncology
Related publications
Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia
Cancer Research
Cancer Research
Oncology
Suboptimal Responses to Imatinib in Chronic Myelogenous Leukemia
Clinical Journal of Oncology Nursing
Oncology
Characteristics of Dasatinib- And Imatinib-Resistant Chronic Myelogenous Leukemia Cells
Clinical Cancer Research
Cancer Research
Oncology
Increased Cortical Bone Mineralization in Imatinib Treated Patients With Chronic Myelogenous Leukemia
Haematologica
Hematology
Chronic Myelogenous Leukemia
Journal of the National Comprehensive Cancer Network : JNCCN
Medicine
Oncology
Imatinib Mesylate Therapy May Overcome the Poor Prognostic Significance of Deletions of Derivative Chromosome 9 in Patients With Chronic Myelogenous Leukemia
Blood
Biochemistry
Immunology
Cell Biology
Hematology
Cancer Acquired Resistance: A New Lesson From Chronic Myelogenous Leukemia
Journal of Bone Marrow Research
An Analysis of Strategic Treatment Interruptions During Imatinib Treatment of Chronic Myelogenous Leukemia With Imatinib-Resistant Mutations
Mathematical Biosciences
Statistics
Genetics
Probability
Molecular Biology
Biochemistry
Applied Mathematics
Microbiology
Simulation
Immunology
Biological Sciences
Medicine
Agricultural
Modeling
Comparison of Branded and Generic Imatinib Plasma Concentrations in Patients With Chronic Myelogenous Leukemia: Unicentric Study
Clinical Lymphoma, Myeloma and Leukemia
Cancer Research
Oncology
Hematology
